Anaptysbio (ANAB) Cash & Equivalents Growth (5y) (2021 - 2026)

Anaptysbio (ANAB) Cash & Equivalents Growth (5y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Anaptysbio 1.55 Bn 1.27 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.65%
Dec 31, 2025 -1.00%
Sep 30, 2025 -12.09%
Jun 30, 2025 -27.50%
Mar 31, 2025 -9.81%
Dec 31, 2024 -6.37%
Sep 30, 2024 0.93%
Jun 30, 2024 -13.29%
Mar 31, 2024 -12.69%
Dec 31, 2023 -20.55%
Sep 30, 2023 -38.27%
Jun 30, 2023 -9.21%
Mar 31, 2023 6.36%
Dec 31, 2022 -2.56%
Sep 30, 2022 17.03%
Jun 30, 2022 18.45%
Mar 31, 2022 11.46%
Dec 31, 2021 57.45%